QIAGEN delivers solid Q4 2024 growth ahead of outlook

1 day ago · Q4 2024: Net sales of $521 million (+2% actual rates, +4% constant exchange rates (CER) core growth); diluted EPS of $0.39 and adjusted diluted EPS of $0.61 Net sales of $525 …

CouponFollow Extension

2%
OFF

QIAGEN Delivers Solid Q4 2024 Growth Ahead Of Outlook

3 weeks from now

1 day ago · Q4 2024: Net sales of $521 million (+2% actual rates, +4% constant exchange rates (CER) core growth); diluted EPS of $0.39 and adjusted diluted EPS of $0.61 Net sales of $525 …

qiagen.com

6%
OFF

QIAGEN Delivers Solid Q4 2024 Growth Ahead Of Outlook

3 weeks from now

1 day ago · QIAGEN delivers solid Q4 2024 growth ahead of outlook. Business Wire ... 30.6% adj. operating income margin up 2.6 percentage points vs. 28.0% in Q4 2023. FY 2024: Exceeded …

yahoo.com

$521
OFF

QIAGEN Delivers Solid Q4 2024 Growth Ahead Of Outlook

3 weeks from now

1 day ago · Q4 2024: Net sales of $521 million; diluted EPS of $0.39 and adjusted diluted EPS of $0.61 Net sales of $525 million CER ahead of outlook for at least $520 million CER and …

nasdaq.com

4%
OFF

QIAGEN Delivers Solid Q4 2024 Growth Ahead Of Outlook

3 weeks from now

1 day ago · QIAGEN expects the solid growth pace in H2 2024 to continue in 2025. Net sales are expected to rise about 4% CER (and core sales growth of about 5% CER). Adjusted diluted …

ft.com

2%
OFF

QIAGEN Delivers Solid Q4 2024 Growth Ahead Of Outlook

3 weeks from now

1 day ago · QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced financial results for the fourth quarter and full-year 2024. Net sales for Q4 2024 increased 2% …

financialcontent.com

2%
OFF

QIAGEN Delivers Solid Q4 2024 Growth Ahead Of Outlook

3 weeks from now

1 day ago · QIAGEN N.V. today announced financial results for the fourth quarter and full-year 2024. Net sales for Q4 2024 increased 2% to $521 million compared to Q4 2023, while sales …

lelezard.com

2%
OFF

QIAGEN Delivers Solid Q4 2024 Growth Ahead Of Outlook

3 weeks from now

1 day ago · QIAGEN delivers solid Q4 2024 growth ahead of outlook Q4 2024: Net sales of $521 million (+2% actual rates, +4% constant exchange rates (CER) core growth); diluted EPS of …

morningstar.com

8%
OFF

QIAGEN Exceeds Outlook For Q4 2023, Led By 8% CER Sales Growth …

3 weeks from now

Feb 6, 2024 · Adjusted diluted EPS were $2.09 CER and exceeded the outlook for at least $2.07 CER. For 2024, QIAGEN has set an outlook for net sales of at least $2.0 billion CER. This …

qiagen.com

$0.61
OFF

QIAGEN Delivers Solid Q4 2024 Growth Ahead Of Outlook – …

3 weeks from now

1 day ago · Adjusted diluted earnings per share (EPS) were $0.61, and CER results of $0.61 were above the outlook for at least $0.60 CER. QIAGEN expects the solid growth pace in H2 2024 …

ft.com

2%
OFF

QIAGEN Delivers Solid Q4 2024 Growth Ahead Of Outlook - Sharewise

3 weeks from now

1 day ago · QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced financial results for the fourth quarter and full-year 2024. Net sales for Q4 2024 increased 2% …

sharewise.com

$521
OFF

QIAGEN Delivers Solid Q4 2024 Growth Ahead Of Outlook

3 weeks from now

1 day ago · Q4 2024: Net sales of $521 million core growth); diluted EPS of $0.39 and adjusted diluted EPS of $0.61 Net sales of $525 million CER ahead of outlook for at least $520 million …

marketscreener.com

4%
OFF

Qiagen N : QIAGEN Delivers Solid Q4 2024 Growth Ahead Of Outlook

3 weeks from now

15 hours ago · Earnings Flash (QGEN) QIAGEN Q4 Adjusted EPS $0.61, vs. FactSet Est of $0.62 Feb. 05: MT Qiagen Sees 2025 Outlook For About 4% CER Sales Growth Feb. 05: RE …

marketscreener.com

6%
OFF

QIAGEN Delivers Solid Q4 2024 Growth Ahead Of Outlook

3 weeks from now

1 day ago · Read Press Release for Qiagen N.V. Common Shares (QGEN) published on Feb. 5, 2025 - QIAGEN delivers solid Q4 2024 growth ahead of outlook ... 30.6% adj. operating …

marketchameleon.com

2%
OFF

QIAGEN Delivers Solid Q4 2024 Growth Ahead Of Outlook

3 weeks from now

QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced financial results for the fourth quarter and full-year 2024. Net sales for Q4 2024 increased 2% to $521 million …

gurufocus.com

$10
OFF

AMGEN REPORTS FOURTH QUARTER AND FULL YEAR 2024 …

3 weeks from now

2 days ago · The Company generated $10.4 billion of free cash flow for the full year 2024 versus $7.4 billion in 2023. The Company's fourth quarter 2024 dividend of $2.25 per share was …

amgen.com

2%
OFF

QIAGEN Delivers Solid Q4 2024 Growth Ahead Of Outlook - ADVFN

3 weeks from now

1 day ago · QGEN Qiagen NV QIAGEN delivers solid Q4 2024 growth ahead of outlook. Q4 2024: Net sales of $521 million (+2% actual rates, +4% constant exchange rates (CER) core …

advfn.com

FAQs about QIAGEN delivers solid Q4 2024 growth ahead of outlook Coupon?

Will QIAGEN (QGEN) deliver a year-over-year increase in earnings?

The market expects Qiagen (QGEN) to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended December 2024. ...

What is QIAGEN's outlook for H2 2024?

Adjusted diluted earnings per share (EPS) were $0.61, and CER results of $0.61 were above the outlook for at least $0.60 CER. QIAGEN expects the solid growth pace in H2 2024 to continue in 2025. Net sales are expected to rise about 4% CER (and core sales growth of about 5% CER). ...

How many times has QIAGEN surpassed consensus EPS estimates?

Over the last four quarters, the company has surpassed consensus EPS estimates three times. Qiagen, which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $521.2 million for the quarter ended December 2024, surpassing the Zacks Consensus Estimate by 0.09%. This compares to year-ago revenues of $509.16 million. ...

Is QIAGEN (Qiq) a good stock to buy now?

For Qiagen, the Most Accurate Estimate is higher than the Zacks Consensus Estimate, suggesting that analysts have recently become bullish on the company's earnings prospects. This has resulted in an Earnings ESP of +2.76%. On the other hand, the stock currently carries a Zacks Rank of #3. ...

How did QIAstat-Dx perform in the second half of 2024?

The company said, “Our solid sales growth in the second half of 2024 mirrors our plans for further strong growth in 2025 as we reconfirm our 2028 targets. QIAstat-Dx exceeded expectations with four FDA clearances for our syndromic testing system in 2024 and one already in 2025, coupled with over 660 placements in 2024 that was ahead of our target. ...

Should you buy Amgen (AMGN) before its earnings release?

However, investors should pay attention to other factors too for betting on this stock or staying away from it ahead of its earnings release. Among the stocks in the Zacks Medical - Biomedical and Genetics industry, Amgen (AMGN) is soon expected to post earnings of $5.01 per share for the quarter ended December 2024. ...